

## **Three Trends in Clinical Trial Data Management**



Multiple industry drivers—the increasing demand for clinical trials, accelerating volume of complex data, and shortage of skilled resources—are causing research organizations to turn to skilled outsourcing partners to manage the backlog of data entry and curation to reduce costs and provide research ready data.

## **Industry Outlook for Clinical Trials**

- Approximately 50% of all clinical trials started in 2022 were in oncology, which are expected to continue. Approximately 30% of phase 2 and 3 clinical trials have
- experienced delayed start dates due to funding challenges and availability of labor. Phase 3 clinical trial durations increased from 2 years in 2010
- to 3.5 years in 2022.
- Clinical trial cost will be emphasized over timeliness. Uncertainty around technology investment will lead sponsors toward legacy clinical trial models versus virtual options.

**Source:** Life Sciences Services Industry Outlook: Winter 2023<sup>1</sup>

# Operational Challenges Impacting Clinical Trial Sites



Research organizations

are experiencing an

51.9%

### 95% reported manual effort is involved in

In surveys of clinical data management professionals:

transformation for clinical trials, and two out of three experienced issues with the process.<sup>3</sup> 58% indicated they are not confident in the quality or completeness of their clinical data


data aggregation, cleaning, and

- from an audit and compliance perspective.4 Key concerns include data completeness (51%), quality (45%), and cleaning (43%).<sup>5</sup>
- In-house clinical teams are spending valuable time cleaning data rather than analyzing it.6
- and EHRs, significant data remains locked in clinical free text.7 50% reported using up to five different data sources, and 37% use between six and ten.8


Despite use of numerous oncology databases

increasing demand for clinical trials in response to the rising need for new and advanced drugs and therapies to address the rising prevalence of diseases such as cancer.

The Rising Costs of Trials and Data Management




failures and delays.9



financial implications for both trial sponsors and administrators.

challenges and

availability of labor. 10




healthcare CEOs.<sup>11</sup> Clinical trials that are delayed, postponed, or cancelled have negative

### **Advantages of Outsourcing Clinical Trial Data Management** to Omega Healthcare

research findings. Data collection, curation, and analysis from multiple sources (including EHR platforms) improves data quality.

RWE data management provides insights to improve decision-making and support

- AI/ML modeling to develop test data sets supports clinical diagnosis and predictive modeling of patient recurrence and outcomes. Centralized data governance and protocol
- management for monitoring and reporting on compliance benefits drug development, off-label FDA approval, and clinical research. Cancer data registry and submissions are
- managed by an experienced CTR team.



Learn more in the white paper,

DOWNLOAD THE WHITE PAPER

- 1 "Life Sciences Services Industry Outlook: Winter 2023," RSM, February 6, 2023 2 "Clinical Research Trends & Insights for 2023," WCG Challenges and Opportunities in Clinical Data Management," Pharma
- Intelligence report sponsored by Oracle, September 2018 5 Ibid
- Markets, March 1, 2023 7 "Use of Natural Language Processing to Extract Clinical Cancer Phenotypes from Electronic Medical Records," NIH National Library of Medicine,

6 "Clinical Trials Outsourcing Global Market Report 2022," Research and

- - 10 Ibid 11 "Clinical Research Trends & Insights for 2023," WCG

8 "Challenges and Opportunities in Clinical Data Management Research Report," Pharma Intelligence and Oracle. September 2018

